Rigel Pharmaceuticals ( (RIGL) ) has released its Q3 earnings. Here is a breakdown of the information Rigel Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rigel Pharmaceuticals, Inc., a biotechnology company based in South San Francisco, focuses on developing therapies for hematologic disorders and cancer. The company is known for its innovative approach in the biotechnology sector, particularly in the treatment of immune thrombocytopenia and acute myeloid leukemia.
In its third-quarter 2025 earnings report, Rigel Pharmaceuticals announced total revenue of $69.5 million, with net product sales reaching a record $64.1 million. The company also reported a significant net income of $27.9 million, showcasing strong financial performance and strategic advancements in its product pipeline.
Key highlights from the report include a 65% increase in net product sales compared to the same period in 2024, driven by the commercial success of products such as TAVALISSE, GAVRETO, and REZLIDHIA. Rigel also made notable progress in its clinical development programs, including the advancement of its Phase 1b study of R289 for lower-risk myelodysplastic syndrome and the initiation of a Phase 2 study in collaboration with The University of Texas MD Anderson Cancer Center.
The company has updated its 2025 revenue guidance to approximately $285 to $290 million, reflecting confidence in continued commercial success and strategic partnerships. Rigel’s financial discipline and robust pipeline development are expected to support positive net income for the full year, while funding ongoing and new clinical programs.
Looking ahead, Rigel Pharmaceuticals remains focused on expanding its commercial operations and advancing its clinical pipeline. The company’s management is optimistic about achieving its financial targets and continuing to deliver innovative treatments for patients with unmet medical needs.